Keep pulling the thread on Pfizer.
In 2025, Pfizer returned $9.8 billion to shareholders through its quarterly dividend.
For the full year 2025, Pfizer's operational revenue grew 6% when excluding its COVID-19 products.
The FDA has approved PADCEF in combination with PEMPRO for patients with muscle-invasive bladder cancer who are ineligible for cisplatin-containing chemotherapy.
In 2026, Pfizer anticipates progress on approximately 20 pivotal studies, with 10 from the Metzera portfolio and four for its anti-PD-1 VGF bispecific antibody.
Pfizer is targeting the first potential approvals for its obesity portfolio to begin in 2028.
Pfizer reported full-year 2025 revenues of $62.6 billion, a 2% operational decline from the previous year.
For the full year 2025, Pfizer reported adjusted diluted earnings per share of $3.22.
Pfizer's portfolio of recently launched and acquired products generated $10.2 billion in revenue for the full year of 2025, growing 14% operationally.
Pfizer recorded approximately $4.4 billion in non-cash tangible asset impairments in Q4 2025 related to certain medicines and pipeline assets.
Pfizer is on track to deliver the majority of its anticipated $7.2 billion in total net cost savings from productivity programs by the end of 2026.
Pfizer forecasts its full-year 2026 revenues will be in the range of $59.5 billion to $62.5 billion.
Pfizer forecasts its full-year 2026 adjusted diluted earnings per share to be in the range of $2.80 to $3.00.